topic

639 Intra-tumor delivery of IFN-alpha by Tie-2 transduced monocytes associated with favorable 2-year survival in unmethylated MGMT GBM patients: preliminary results of TEM-GBM phase 1/2a study
Carlo Russo, Bernhard Gentner, Marica Eoli, Francesca Farina, Alessia Capotondo, Elena Anghileri, Matteo Barcella, Valentina Brambilla, Matteo Carrabba, Valeria Cuccarini, Giorgio D’Alessandris, Francesco Di Meco, Valeria Ferla, Paolo Ferroli, Filippo Gagliardi, Federico Legnani, Stefania Mazzoleni, Alessandro Olivi, Roberto Pallini, Marco Saini, Silvia Snider, Karen Mullen, Luigi Naldini, Gaetano Finocchiaro, Fabio Ciceri

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A731; DOI: 10.1136/jitc-2023-SITC2023.0639
640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
Ecaterina Dumbrava, Bartosz Chmielowski, Dale Shepard, Daniel Vaena, Drew Rasco, Manish Sharma, Erika Hamilton, Kyriakos P Papadopoulos, Judy S Wang, Eran Ophir, Pierre Ferre, Inbal Barbiro, Gady Cojocaru, Adeboye H Adewoye, Manish Patel

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A732; DOI: 10.1136/jitc-2023-SITC2023.0640
641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma
Marina Baretti, Brian Ladle, Julie Nauroth, Hao Wang, Jennifer Durham, Christopher Thoburn, Anna Ferguson, Alex Thompson, Madalena Brancati, Paige Griffith, Zeal Kamdar, Allison Kirk, Neeha Zaidi, Amanda Huff, Won Ho, Mark Furth, Paul Thomas, Elizabeth M Jaffee, Mark Yarchoan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A733-A734; DOI: 10.1136/jitc-2023-SITC2023.0641
642 TGFβ-based immune modulatory vaccines
Mads H Andersen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A735; DOI: 10.1136/jitc-2023-SITC2023.0642
643 A first in human phase I/IIa trial of personalized tumor-trained lymphocytes, pTTL, derived from regional lymph nodes for treatment of colorectal cancer
Sofia Berglund, Anne-Laure Joly, Erwan Le Maitre, Kelly Day, Luigi Notari, Claudia Carvalho-Queiroz, Ola Nilsson, Andreas Kaiser, Maximilian Kordes, Jeffrey Yachnin, Mattias Carlsten, Stephan Mielke, Abbas Chabok, Maziar Nikberg, Ahmed Salim Tarfy, Andrea Salmén, Samuel Svensson, Hanjing Xie, Guro Gafvelin, Hans Grönlund

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A736; DOI: 10.1136/jitc-2023-SITC2023.0643
645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors
Seung-Tae Kim, Hong Jae Chon, Do-Youn Oh, Jaspreet Grewal, Sun Young Rha, Anthony El-Khoueiry, Baek-Yeol Ryoo, Jeongjun Kim, Hyunji Ahn, Seung-Hee Ryu, Jinho Choi, Bae Jung Choi, Jiye Ahn, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A738; DOI: 10.1136/jitc-2023-SITC2023.0645
647 PERIO-03: Pressure enabled intrapancreatic delivery of SD-101 with checkpoint blockade for locally advanced pancreatic adenocarcinoma – Initial safety and feasibility experience
Michael S Lee, Rahul Sheth, Joshua D Kuban, Ethan Ludmir, Charla McMichael, Jason LaPorte, Lindsay Laudal, Ann-Marie Hulstine, Steven Katz, Shubham Pant

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A739; DOI: 10.1136/jitc-2023-SITC2023.0647
649 Phase 1a open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer
Jia Liu, Timothy Price, Niall Tebbutt, Eugene Hsu, Rafid Al-Asady, Darren R Shafren, Naomi Croll, Mark Wong

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A740; DOI: 10.1136/jitc-2023-SITC2023.0649
650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
Natalie Lucas, Nicholas Venturini, Samarth Hegde, Raphaël Mattiuz, Clotilde Hennequin, Jessica Le Berichel, Theodore Chin, Amanda Reid, Leanna Troncoso, David Greenwald, Ari Grinspan, Steve Itzkowitz, Aimee L Lucas, Dana Zalkin, Celina Ang, Ana Acuna-Villaorduna, Peter Kozuch, Sergey Khaitov, Alex Ky-Miyasaka, Umut Sarpel, Randolph Steinhagen, Patricia Sylla, Gunther Kretschmar, Zheng Zhu, Noam Harpaz, Qingqing Liu, John Paulsen, Xintong Wang, Stephen Ward, Deborah Doroshow, Alexandros D Polydorides, Deirdre Cohen, Miriam Merad, Kathy Wu, Gabriela Fazilov, Gary Shelton, Thomas Marron, Amber Cameron, Megan Yuan, Lisa Fitzgerald

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A741; DOI: 10.1136/jitc-2023-SITC2023.0650
651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors
Devalingam Mahalingam, Angela Alistar, Alain Mita, Jeongjun Kim, Hyunji Ahn, Jinho Choi, Seung-Hee Ryu, Jiye Ahn, Bae Jung Choi, Hwankyu Kang, Yeong-In Yang, Seung-Joo Lee, Borami Jeon, Stefan Proniuk, Kiyean Nam, Anthony El-Khoueiry

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A742; DOI: 10.1136/jitc-2023-SITC2023.0651

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages